Marcy l'Etoile, France - May 4th, 2004. A major player in the field of infectious disease, bioMérieux, and its exclusive distributor for South Africa, Omnimed, have just won a most important tender for the National Health Laboratory Services of South Africa as regards the fight against the...
Marcy l'Etoile, France - April 20th, 2004. The European Patent Office’s Board of Appeal has found in favour of bioMérieux in the opposition to its European patent for the Boom technology.
European Patent No. 0,389,063 granted in 1997 is owned by bioMérieux further to the...
Marcy l'Etoile, France - April 2nd, 2004. bioMérieux announces the introduction of NucliSens miniMAG and NucliSens Magnetic Extraction Reagents, two key components of the company’s next generation nucleic acid extraction technology.
“These two products make up a novel...
Marcy-l’Etoile, France - March 26, 2004. bioMérieux announces U.S. FDA-CBER (1) Premarket Notification 510(k) clearance of the recently launched, innovative polycarbonate BacT/ALERT BPA and BacT/ALERT BPN culture bottles for microbial quality control testing of leukocyte-reduced single...
Marcy l'Etoile, France - February 24th, 2004. bioMérieux announces the launch of FoodExpert-ID, the first high-density DNA chip for food and animal feed testing. The FoodExpert-ID test, powered by Affymetrix® GeneChip® technology, will make it possible to verify the animal species...
Marcy l'Etoile, France - January 14th, 2004.
bioMerieux, is a major player in the field of in vitro infectious disease diagnostics. Founded in 1963 in France, the company designs, develops, manufactures and markets reagents and automated instruments for medical analyses. Today,more...
Marcy l'Etoile, France - January 8th, 2004. bioMérieux has received CE Mark certifications for all of its in vitro diagnostic (IVD) products currently marketed in the European Union (EU). In compliance with the requirements of the 98/79/EC directive for CE Marking, which became applicable on...
Cepheid (NASDAQ: CPHD) today announced that it has entered into a strategic commercial relationship with bioMerieux for bioMerieux to develop DNA testing products embodying its proprietary NASBA (Nucleic Acid Sequence-Based Amplification) technology to be run on...
